European Journal of Cancer
Volume 41, Issue 13 , Pages 1955-1968 , September 2005

Curcumin: The story so far

  • R.A. Sharma

      Affiliations

    • Corresponding Author InformationCorresponding author. Present address: Radiotherapy Department, Royal Marsden Hospital NHS Trust, Downs Road, Sutton SM2 5PT, UK. Tel.: +44 208 642 6011; fax: +44 208 661 3127.
    • ,
  • A.J. Gescher
    • ,
  • W.P. Steward

Received 15 March 2005 ,Accepted 13 May 2005.

References 

  1. Brouk B. Plants consumed by man. New York: Academic Press; 1975;p. 331
  2. Eigner D, Sholz D. Ferula asa-foetida and curcuma longa in traditional medical treatment and diet in Nepal. J Ethnopharmacol. 1999;67:1–6
  3. Milobedzka J, Kostanecki V, Lampe V. Structure. Chem Ber. 1910;43:2163
  4. Heath DD, Khwaja F, Rock CL. Curcumin content of turmeric and curry powders. FASEB J. 2004;18:A125
  5. Ammon HP, Wahl MA. Pharmacology of curcuma longa. Planta Med. 1991;57:1–7
  6. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23:363–398
  7. Joe B, Vijaykumar M, Lokesh BR. Biological properties of curcumin – cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr. 2004;44:97–111
  8. Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal. 1997;15:1867–1876
  9. Jovanovic SV, Steenken S, Boone CW, et al. H-Atom transfer is a preferred antioxidant mechanism of curcumin. J Am Chem Soc. 1999;121:9677–9681
  10. Lin JK, Pan MH, Shiau SYL. Recent studies on the biofunctions and biotransformations of curcumin. Biofactors. 2000;13:153–158
  11. Tonnesen HH, Karlsen J. Studies on curcumin and curcuminoids: VI – kinetics of curcumin degradation in aqueous solution. Z Lebensm Unters Forsch. 1985;180:402–404
  12. Tonnesen HH, Karlsen J, van Henegouwen GB. Studies on curcumin and curcuminoids: VIII – photochemical stability of curcumin. Z Lebensm Unters Forsch. 1986;183:116–122
  13. Huang MT, Ma W, Lu YP, et al. Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion. Carcinogenesis. 1995;16:2493–2497
  14. Sreejayan R, Rao MN. Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol. 1994;46:1013–1016
  15. Mau JL, Lai EYC, Wang NP, et al. Composition and antioxidant activity of the essential oil from Curcuma zedoaria. Food Chem. 2003;82:583–591
  16. Wahlstrom B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol. 1978;43:86–92
  17. Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicol. 1980;16:259–265
  18. Ravindranath V, Chandrasekhara N. Metabolism of curcumin – studies with [3H] curcumin. Toxicol. 1981;22:337–344
  19. Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin [1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] in the rat. Xenobiotica. 1978;8:761–768
  20. Ravindranath V, Chandrasekhara N. In vitro studies on the intestinal absorption of curcumin in rats. Toxicol. 1981;20:251–257
  21. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Met Dispos. 1999;27:486–494
  22. Ireson C, Orr S, Jones DJL, et al. Characterization of metabolites of the chemopreventive agent curcumin in humans and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 2001;61:1058–1064
  23. Ireson CR, Jones DJL, Orr S, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidem Biomar Prevent. 2002;11:97–104
  24. Sharma RA, Ireson CR, Verschoyle RD, et al. Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res. 2001;7:1452–1458
  25. Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64:353–356
  26. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21:2895–2900
  27. Ruffin MT, Normolle DP, Heath DD, et al. Dose escalation of curcumin in healthy adults. Cancer Epidem Biomar Prevent. 2003;12(Part 2 Suppl. S):1324S
  28. Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001;7:1894–1900
  29. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10:6847–6854
  30. Garcea G, Berry DP, Jones DJL, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidem Biomar Prevent. 2005;14:120–125
  31. Garcea G, Jones DJL, Singh R, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer. 2004;90:1011–1015
  32. NCI , DCPC . Clinical development plan: curcumin. J Cell Biochem. 1996;26S:72–85
  33. Gupta B, Kulshrestha CK, Sristava RK, et al. Mechanisms of curcumin induced gastric ulcer in rats. Indian J Med Res. 1980;71:806–814
  34. Perkins S, Verschoyle RD, Hill KA, et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the Min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidem Biomar Prevent. 2002;11:535–540
  35. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res. 1980;71:632–634
  36. Chan MM, Huang HI, Fenton MR, et al. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol. 1998;55:1955–1962
  37. Pereira MA, Grubbs CJ, Barnes , et al. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis. 1996;17:1305–1311
  38. Hanif R, Qiao L, Shiff SJ, et al. Curcumin, a natural plant phenolic food additive inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J Lab Clin Med. 1997;130:576–584
  39. Chen H, Zhang ZS, Zhang YL, et al. Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cell lines. Anticancer Res. 1999;19:3675–3680
  40. Mori H, Niwa K, Zhang Q, et al. Cell proliferation in cancer prevention; effects of preventive agents on estrogen-related endometrial carcinogenesis model and on an in vitro model in human colorectal cells. Mutat Res Fund Mol Mech. 2001;480:201–207
  41. Jiang MC, Yang Yen HF, Yen JJY, et al. Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer. 1996;26:111–120
  42. Simon A, Allais DP, Duroux JL, et al. Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure–activity relationships. Cancer Lett. 1998;129:111–116
  43. Gautam SC, Yong YX, Pndolia KR, et al. Nonselective inhibition of proliferation of transformed and nontransformed cells by the anticancer agent curcumin (diferuloylmethane). Biochem Pharmacol. 1998;55:1333–1337
  44. Plummer S, Wakelin D, Bouer M, et al. Inhibition of growth of colon tumour cells by curcumin correlates with inhibition of the IkB kinase and down regulation of cyclin D1. Br J Cancer. 2000;83(Suppl. 1):20
  45. Han SS, Chung ST, Robertson DA, et al. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol. 1999;93:152–161
  46. Bhaumik S, Jyothi MD, Khar A. Differential modulation of nitric oxide production by curcumin in host macrophages and NK cells. FEBS Lett. 2000;483:78–82
  47. Yan CH, Jamaluddin MS, Aggarwal B, et al. Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol Cancer Ther. 2005;4:233–241
  48. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer - I. Prostate Cancer Dis. 2000;3:84–93
  49. Chen AP, Xu J. Activation of PPAR gamma by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol. 2005;288:G447–G456
  50. Kuo ML, Huang TS, Lin JK. Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. Biochim Biophys Acta. 1996;1317:95–100
  51. Ozaki K, Kawata Y, Amano S, et al. Stimulatory effect of curcumin on osteoclast apoptosis. Biochem Pharmacol. 2000;59:1577–1581
  52. Tsvetkov P, Asher G, Reiss V, et al. Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc Natl Acad Sci USA. 2005;102:5535–5540
  53. Chendil D, Ranga RS, Meigooni D, et al. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene. 2004;23:1599–1607
  54. Baatout S, Derradji H, Jacquet P, et al. Effect of curcuma on radiation-induced apoptosis in human cancer cells. Int J Oncol. 2004;24:321–329
  55. Inano H, Onoda M. Radioprotective action of curcumin extracted from Curcuma longa Linn. Int J Radiat Oncol Biol Phys. 2002;53:735–743
  56. Sharma A, Gautam S, Jadhav SS. Spice extracts as dose-modifying factors in radiation inactivation of bacteria. J Agric Food Chem. 2000;48:1340–1344
  57. Dahl TA, McGowan WM, Shand MA, et al. Photokilling of bacteria by the natural dye curcumin. Arch Microbiol. 1989;151:183–185
  58. Tsao SM, Yin MC. Enhanced inhibitory effect from interaction of curcumin with amphotericin B or fluconazole against candida species. J Food Drug Anal. 2000;8:208–212
  59. de Clercq E. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med Res Rev. 2000;20:323–349
  60. Huang TS, Lee SC, Lin JK. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci USA. 1991;88:5292–5296
  61. Chen YR, Tan TH. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene. 1998;17:173–178
  62. Scott DW, Loo G. Curcumin-induced GADD153 gene up-regulation in human colon cancer cells. Carcinogenesis. 2004;25:2155–2164
  63. Gao X, Kuo J, Jiang H, et al. Immunomodulatory activity of curcumin: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity and cytokine production in vitro. Biochem Pharmacol. 2004;68:51–61
  64. Morin D, Barthelemy S, Zini R, et al. Curcumin induces the mithochondrial permeablility transition pore mediated by membrane protein thiol oxidation. FEBS Lett. 2001;495:131–136
  65. Jana NR, Dikshit P, Goswami A, et al. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem. 2004;279:11680–11685
  66. Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 1995;55:259–266
  67. Sharma RA, Farmer PB. Biological relevance of adduct detection to the chemoprevention of cancer. Clin Cancer Res. 2004;10:4901–4912
  68. Kawamori T, Lubet R, Steele VE, et al. Chemopreventative effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res. 1999;59:597–601
  69. Mahmoud NN, Carothers AM, Grunberger D, et al. Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis. 2000;21:921–927
  70. Samaha HS, Kelloff GJ, Steele V, et al. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res. 1997;57:1301–1305
  71. Luongo C, Moser AR, Gledhill S, et al. Loss of Apc(+) in intestinal adenomas from Min mice. Cancer Res. 1994;54:5947–5952
  72. Conney AH. Enzyme induction and dietary chemicals as approaches to cancer chemoprevention: the seventh DeWitt S. Goodman Lecture. Cancer Res. 2003;63:7005–7031
  73. Li N, Chen X, Liao J, et al. Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis. 2002;23:1307–1313
  74. Khafif A, Schantz SP, Chou TC, et al. Quantitation of chemopreventive synergism between (−)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis. 1998;19:419–424
  75. Liu Y, Chang RL, Cui XX, et al. Synergistic effects of curcumin on all-trans retinoic acid- and 1alpha, 25-dihydroxyvitamin D3-induced differentiation in human promyelocytic leukaemia HL-60 cells. Oncol Res. 1997;9:19–29
  76. Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science. 2004;304:600–602
  77. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst. 1998;90:1609–1620
  78. Sharma RA. Translational medicine: targetting cyclooxygenase isozymes to prevent cancer. Quart J Med. 2002;95:267–273
  79. Zhang F, Altorki NK, Mestre JR, et al. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis. 1999;20:445–451
  80. Plummer SM, Holloway KA, Manson MM, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex. Oncogene. 1999;18:6013–6020
  81. Yin M-J, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature. 1998;396:77–78
  82. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705–716
  83. Gescher A, Sharma RA, Steward WP. Cancer chemoprevention by dietary constituents: a tale of failure and promise. Lancet Oncol. 2001;2:371–379
  84. Firozi PF, Aboobaker VS, Bhattacharya RK. Action of curcumin on the cytochrome P450-system catalyzing the activation of aflatoxin B1. Chem-Biol Interact. 1996;100:41–51
  85. Ciolino HP, Daschner PJ, Wang TT, et al. Effect of curcumin on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells. Biochem Pharmacol. 1998;56:197–206
  86. Singh SV, Hu X, Srivastava SK, et al. Mechanism of inhibition of benzo[a]pyrene-induced forestomach cancer in mice by dietary curcumin. Carcinogenesis. 1998;19:1357–1360
  87. Susan M, Rao MNA. Induction of glutathione S-transferase activity by curcumin in mice. Drug Res. 1992;42:962–964
  88. Piper JT, Singhal SS, Salameh M, et al. Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. Int J Biochem Cell Biol. 1998;30:445–456
  89. Nijhoff WA, Groen GM, Peters WHM. Induction of rat hepatic and intestinal glutathione S-transferases and glutathione by dietary naturally occurring anticarcinogens. Int J Oncol. 1993;3:1131–1139
  90. Dinkova-Kostova AT, Talalay P. Relation of structure of curcumin analogs to their potencies as inducers of Phase 2 detoxification enzymes. Carcinogenesis. 1999;20:911–914
  91. Hayes JD, Pulford DJ. The glutathione S-transferases supergene family. Crit Rev Biochem Mol Biol. 1995;30:445–600
  92. Duvoix A, Delhalle S, Blasius R, et al. Effect of chemopreventive agents on glutathione S-transferase P1-1 gene expression mechanisms via activating protein 1 and nuclear factor kappaB inhibition. Biochem Pharmacol. 2004;68:1101–1111
  93. Joe B, Lokesh BR. Role of capsaicin, curcumin and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochim Biophys Acta. 1994;1224:255–263
  94. Tonnesen HH, Greenhill JV. Studies on curcumin and curcuminoids. XXII. Curcumin as a reducing agent and as a radical scavenger. Int J Pharmaceut. 1992;87:79–87
  95. Kunchandy E, Rao MNA. Oxygen radical scavenging activity of curcumin. Int J Pharmaceut. 1990;58:237–240
  96. Reddy AC, Lokesh BR. Studies on anti-inflammatory activity of spice principles and dietary n-3 polyunsaturated fatty acids on carrageenan-induced inflammation in rats. Ann Nutr Met. 1994;38:349–358
  97. Ahsan H, Parveen N, Khan NU, et al. Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin. Chem-Biol Interact. 1999;121:161–175
  98. Nair J, Strand S, Frank N, et al. Apoptosis and age-dependant induction of nuclear and mitochondrial etheno-DNA adducts in Long-Evans Cinnamon (LEC) rats: enhanced DNA damage by dietary curcumin upon copper accumulation. Carcinogenesis. 2005;26:1307–1315
  99. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 2001;2:149–156
  100. deRojas-Walker T, Tamir S, Ji H, et al. Nitric oxide induces oxidative damage in addition to deaminiation in macrophage DNA. Chem Res Toxicol. 1995;8:473–477
  101. Laval F, Wink DA. Inhibition of nitric oxide of the repair protein O6-methylguanine-DNA-methyltransferase. Carcinogenesis. 1994;15:443–447
  102. Graziewicz M, Wink DA, Laval F. Nitric oxide inhibits DNA ligase activity: potential mechanisms for NO-mediated DNA damage. Carcinogenesis. 1996;17:2501–2505
  103. Ambs S, Bennett WP, Merrium WG, et al. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst. 1999;91:86–88reply 1510–1511
  104. von Knethen A, Brune B. Cyclooxygenase-2: an essential regulator of NO-mediated apoptosis. FASEB J. 1997;11:887–895
  105. von Knethen A, Callsen D, Brune B. NF-kB and AP-1 activation by nitric oxide attenuated apoptotic death in RAW 264.7 macrophages. Mol Biol Cell. 1999;10:361–370
  106. Brouet I, Ohshima H. Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun. 1995;206:533–540
  107. Greene HSN. Heterologous transplantation of mammalian tumors. The transfer of human tumors to alien species. J Exp Med. 1941;73:461–486
  108. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757–1763
  109. Sharma RA, Harris AL, Dalgleish AG, et al. Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncol. 2001;2:726–732
  110. Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med. 1998;4:376–383
  111. Thaloor D, Singh AK, Sidhu GS, et al. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. Cell Growth Differ. 1998;9:305–312
  112. Menon LG, Kuttan R, Kuttan G. Anti-metastatic activity of curcumin and catechin. Cancer Lett. 1999;141:159–165
  113. Chan MMY. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol. 1995;49:1551–1556
  114. Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res. 1999;39:41–47
  115. Gupta B, Ghosh B. Curcuma longa inhibits TNF-alpha induced expression of adhesion molecules on human umbilical vein endothelial cells. Int J Immnopharmacol. 1999;21:745–757
  116. Jaiswal AS, Marlow BP, Gupta N, et al. Beta-catenin-mediated transactivation and cell–cell adhesion pathways are important in curcumin (diferuloylmethane)-induced growth arrest and apopstosis in colon cancer cells. Oncogene. 2002;21:8414–8427
  117. Raysid A, Lelo A. The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther. 1999;13:245–249
  118. Plummer SM, Hill KA, Festing MFW, et al. Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol Biomarkers Prev. 2001;10:1295–1299
  119. Kim HY, Park EJ, Joe EH, et al. Curcumin suppresses janus kinase-STAT inflammatory signalling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J Immunol. 2003;171:6072–6079
  120. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol. 2003;171:3863–3871
  121. Sugimoto K, Hanai H, Tozawa K, et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterol. 2002;123:1912–1922
  122. Satoskar RR, Shah SJ, Shenoy SG. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with post-operative inflammation. Int J Clin Pharmacol Ther Toxicol. 1986;24:651–654
  123. Lal B, Kapoor AK, Asthana OP, et al. Efficacy of curcumin in the managememtn of chronic anterior uveitis. Phytother Res. 1999;13:318–322
  124. Lal B, Kapoor AK, Agrawal Pk, et al. Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother Res. 2000;14:443–447
  125. Martin-Cordero C, Lopez-Lazaro M, Galvez M, et al. Curcumin as a DNA topoisomerase II poison. J Enzyme Inhib Med Chem. 2003;18:505–509
  126. Kuttan R, Sudheeran PC, Josph CD. Turmeric and curcumin as topical agents in cancer therapy. Tumori. 1987;73:29–31

PII: S0959-8049(05)00477-6

doi: 10.1016/j.ejca.2005.05.009

European Journal of Cancer
Volume 41, Issue 13 , Pages 1955-1968 , September 2005

Article Tools

* Image Usage & Resolution